uric acid has been researched along with Tuberculosis, Multidrug-Resistant in 1 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hyperuricemia was defined as serum uric acid levels exceeding 7." | 4.31 | Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment. ( Jeong, SH; Kho, BG; Kim, TO; Kim, YI; Kwon, YS; Lee, JK; Lim, SC; Na, YO; Shin, HJ; Yoon, JY, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, HJ | 1 |
| Yoon, JY | 1 |
| Na, YO | 1 |
| Lee, JK | 1 |
| Kho, BG | 1 |
| Kim, TO | 1 |
| Kim, YI | 1 |
| Lim, SC | 1 |
| Jeong, SH | 1 |
| Kwon, YS | 1 |
1 other study available for uric acid and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment.
Topics: Antitubercular Agents; Female; Humans; Hyperuricemia; Male; Myocardial Ischemia; Retrospective Studi | 2023 |